Too Little, Too Late For GSK/Janssen's Sirukumab in RA?

Full data for the Phase III SIRROUND-D study of GlaxoSmithKline PLC/Janssen Pharmaceuticals Inc.'s sirukumab show early and good separation over placebo in rheumatoid arthritis, but the third-placed anti-IL6 product will have to work hard to catch up with its more advanced rivals, Actemra (tocilizumab) and sarilumab.